Kingworld Medicines Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Kingworld Medicines Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 22.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kingworld Medicines Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 1,052 | 31 | 44 | 117 | N/A |
| 3/31/2024 | 1,065 | 35 | -10 | 80 | N/A |
| 12/31/2023 | 1,079 | 38 | -63 | 42 | N/A |
| 9/30/2023 | 1,085 | 37 | -15 | 110 | N/A |
| 6/30/2023 | 1,091 | 36 | 34 | 177 | N/A |
| 3/31/2023 | 1,024 | 29 | 64 | 182 | N/A |
| 12/31/2022 | 958 | 23 | 93 | 187 | N/A |
| 9/30/2022 | 905 | 29 | 66 | 159 | N/A |
| 6/30/2022 | 852 | 35 | 40 | 131 | N/A |
| 3/31/2022 | 850 | 33 | 31 | 106 | N/A |
| 12/31/2021 | 847 | 30 | 23 | 81 | N/A |
| 9/30/2021 | 858 | 26 | 76 | 111 | N/A |
| 6/30/2021 | 868 | 21 | 129 | 141 | N/A |
| 3/31/2021 | 807 | 17 | 121 | 132 | N/A |
| 12/31/2020 | 745 | 12 | 114 | 124 | N/A |
| 9/30/2020 | 749 | 16 | 90 | 99 | N/A |
| 6/30/2020 | 752 | 20 | 66 | 74 | N/A |
| 3/31/2020 | 865 | 32 | 95 | 103 | N/A |
| 12/31/2019 | 978 | 43 | 124 | 133 | N/A |
| 9/30/2019 | 1,010 | 45 | 79 | 88 | N/A |
| 6/30/2019 | 1,041 | 46 | 34 | 44 | N/A |
| 3/31/2019 | 1,060 | 44 | 42 | 53 | N/A |
| 12/31/2018 | 1,079 | 41 | 51 | 62 | N/A |
| 9/30/2018 | 1,079 | 49 | 60 | 85 | N/A |
| 6/30/2018 | 1,079 | 56 | 70 | 108 | N/A |
| 3/31/2018 | 1,055 | 54 | N/A | 90 | N/A |
| 12/31/2017 | 1,031 | 51 | N/A | 72 | N/A |
| 9/30/2017 | 1,088 | 50 | N/A | 58 | N/A |
| 6/30/2017 | 1,145 | 49 | N/A | 43 | N/A |
| 3/31/2017 | 1,099 | 48 | N/A | 20 | N/A |
| 12/31/2016 | 1,054 | 47 | N/A | -4 | N/A |
| 9/30/2016 | 909 | 41 | N/A | 20 | N/A |
| 6/30/2016 | 764 | 35 | N/A | 44 | N/A |
| 3/31/2016 | 739 | 34 | N/A | 74 | N/A |
| 12/31/2015 | 714 | 32 | N/A | 103 | N/A |
| 9/30/2015 | 711 | 34 | N/A | 56 | N/A |
| 6/30/2015 | 708 | 36 | N/A | 10 | N/A |
| 3/31/2015 | 684 | 37 | N/A | 2 | N/A |
| 12/31/2014 | 660 | 38 | N/A | -5 | N/A |
| 9/30/2014 | 640 | 43 | N/A | -21 | N/A |
| 6/30/2014 | 619 | 48 | N/A | -38 | N/A |
| 3/31/2014 | 587 | 48 | N/A | -44 | N/A |
| 12/31/2013 | 555 | 47 | N/A | -50 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1110's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1110's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1110's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1110's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1110's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1110's Return on Equity is forecast to be high in 3 years time